HDACI-Enhanced Genome Engineering in Hematopoietic Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for genome engineering of CD34+ hematopoietic stem cells, particularly long-term hematopoietic stem cells (LT-HSCs), face challenges such as low efficiency of gene modification, limited survival and proliferation in vitro, and difficulty in maintaining nuclease-modified cells, leading to poor engraftment and long-term efficacy in transplantation therapies.
Innovation Solution
The use of specific culture conditions and factors like histone deacetylase inhibitors (HDACIs), prostaglandins, and other compounds to enhance stem cell expansion and maintain stemness, combined with nuclease-mediated targeted integration methods, increases the efficiency of gene modification and DNA repair pathway choice, particularly in LT-HSCs, thereby improving the percentage of modified cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If nuclease-mediated genome engineering is applied to LT-HSCs, then targeted gene modification can be achieved, but the efficiency of gene modification remains low
Solution Approach 1:
The patent applies parameter changes by treating LT-HSCs with HDACIs (histone deacetylase inhibitors) to alter chromatin structure and epigenetic states, thereby making the genome more accessible to nucleases and improving gene modification efficiency. This chemical treatment modifies the physical-chemical parameters of the chromatin, enabling better nuclease access and enhanced HDR activity without changing the fundamental genome engineering approach
Solution Approach 2:
The patent introduces culture conditions and chemical factors (HDACIs, prostaglandins, cytokines) as intermediaries between the nuclease treatment and the cellular response. These intermediaries prepare the cells by modulating chromatin accessibility, cell cycle distribution, and DNA repair pathway choice, thereby mediating enhanced gene modification efficiency when nucleases are applied
2Manufacturing precision
If nuclease-mediated cleavage is performed in LT-HSCs, then targeted integration can be achieved, but the survival and proliferation of modified cells in vitro is limited
Solution Approach 1:
The patent applies preliminary action by treating LT-HSCs with HDACIs and optimizing culture conditions before nuclease delivery. This pre-treatment prepares the cells by enhancing chromatin accessibility, modulating cell cycle phases to favor HDR, and improving overall cellular health, thereby enabling successful nuclease-mediated integration while maintaining cell survival and proliferation capabilities
Solution Approach 2:
The patent changes physiological parameters through chemical treatments (HDACIs, prostaglandins, cytokines) to create an optimal state for both nuclease activity and cell survival. These parameter changes include chromatin accessibility, cell cycle distribution, and metabolic state, allowing targeted integration to proceed while preserving cell viability and proliferative potential
3Stability of the object's composition
If standard culture conditions are used for LT-HSCs, then cells can be maintained, but the efficiency of gene modification and maintenance of stemness is poor
Solution Approach 1:
The patent applies parameter changes by introducing HDACIs and optimizing culture conditions to simultaneously maintain stemness and enhance gene modification efficiency. The chemical treatments modify chromatin structure and epigenetic parameters without inducing differentiation, thereby improving nuclease accessibility and HDR activity while preserving the stem cell phenotype and long-term repopulating capacity
Solution Approach 2:
The patent applies multi-functionality by using HDACIs and optimized culture conditions that serve multiple purposes: maintaining stemness, enhancing chromatin accessibility, modulating cell cycle distribution, and improving DNA repair efficiency. These interventions simultaneously address multiple requirements for successful genome engineering in LT-HSCs
4Manufacturing precision
If HDACIs and culture factors are used to enhance gene modification efficiency, then the percentage of modified cells increases, but the complexity of the culture system increases
Solution Approach 1:
The patent applies parameter changes through chemical treatments (HDACIs, prostaglandins, cytokines) that can be added to existing culture media without requiring fundamental system redesign. These chemical parameters are integrated into standard culture protocols, enhancing gene modification efficiency while maintaining relative simplicity of the overall culture system
Data Source
AI summary
The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic stem cell.